Literature DB >> 15902287

What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?

S D Turner1, D R Alexander.   

Abstract

The nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is generated as a t(2;5) chromosomal breakpoint product, typically in CD30(+) anaplastic large cell lymphomas. Activation of the NPM-ALK tyrosine kinase by NPM dimerisation causes autophosphorylation at multiple tyrosine residues and the consequent recruitment of a 'signalosome' that couples the fusion protein to pathways regulating mitogenesis and apoptosis. This review focuses on recent advances in our understanding of the transforming signals induced by this fusion protein in mouse models.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902287     DOI: 10.1038/sj.leu.2403797

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  20 in total

1.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

Authors:  Anna V Galkin; Jonathan S Melnick; Sungjoon Kim; Tami L Hood; Nanxin Li; Lintong Li; Gang Xia; Ruo Steensma; Greg Chopiuk; Jiqing Jiang; Yongqin Wan; Peter Ding; Yi Liu; Fangxian Sun; Peter G Schultz; Nathanael S Gray; Markus Warmuth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

2.  A novel role for IL-22R1 as a driver of inflammation.

Authors:  Ram Savan; Adelle P McFarland; Della A Reynolds; Lionel Feigenbaum; Karthika Ramakrishnan; Megan Karwan; Hidekazu Shirota; Dennis M Klinman; Kieron Dunleavy; Stefania Pittaluga; Stephen K Anderson; Raymond P Donnelly; Wyndham H Wilson; Howard A Young
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

3.  Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma.

Authors:  W Piao; D Chau; L M Yue; Y-L Kwong; E Tse
Journal:  Leukemia       Date:  2016-10-31       Impact factor: 11.528

Review 4.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

5.  Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion.

Authors:  Alyaksandr V Nikitski; Susan L Rominski; Mamta Wankhede; Lindsey M Kelly; Federica Panebianco; Guillermo Barila; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Am J Pathol       Date:  2018-08-18       Impact factor: 4.307

6.  Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.

Authors:  Lin Qiu; Raymond Lai; Quan Lin; Esther Lau; David M Thomazy; Daniel Calame; Richard J Ford; Larry W Kwak; Robert A Kirken; Hesham M Amin
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

7.  The natural product avrainvillamide binds to the oncoprotein nucleophosmin.

Authors:  Jeremy E Wulff; Romain Siegrist; Andrew G Myers
Journal:  J Am Chem Soc       Date:  2007-10-25       Impact factor: 15.419

Review 8.  Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.

Authors:  Fabrizio Tabbò; Maurilio Ponzoni; Raul Rabadan; Francesco Bertoni; Giorgio Inghirami
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

9.  Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity.

Authors:  Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2009-03-13

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.